FDA
-
-
-
-
-
-
-
MIMEDX Announces Record Fourth Quarter and Full Year 2025 Operating and Financial Results
-
-
-
-
-
-
-
MIMEDX Announces Record Second Quarter 2025 Operating and Financial Results
-
-
-
-
-
-
-
THIRD DEFENDANT FIGHTS BACK AGAINST MiMEDX, CLAIMING 'DISREPUTABLE AND UNLAWFUL BUSINESS PRACTICES'
-
-
-
-
-
-
-
MIMEDX Provides Update on AXIOFILL® Request for Designation (“RFD”) from FDA
-
-
-
-
-
-
-
MiMedx Group (MDXG) Confirms Fourth Quarter and Full Year 2022 Net Sales Expectations, Comments on Evolving Medicare Reimbursement Landscape and Provides Corporate Updates
-
-
-
-
-
-
-
MIMEDX Board Chair Dr. M. Kathleen Behrens Writes Letter to Fellow Shareholders
-
-
-
-
-
-
-
MIMEDX Outlines Long-Term Value Creation Strategy at Virtual Investor Day
-
328,600 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

